<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679653</url>
  </required_header>
  <id_info>
    <org_study_id>KD200010</org_study_id>
    <nct_id>NCT00679653</nct_id>
  </id_info>
  <brief_title>Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives</brief_title>
  <acronym>HOS</acronym>
  <official_title>Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of sibutramine treatment on weight reduction and blood pressure
      improvement in three groups with antihypertensive therapy whose blood pressure was not
      adequately controlled with antihypertensive combination treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>verapamil/trandolapril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metoprolol/HCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>felodipine/ramipril</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sibutramine</intervention_name>
    <description>8-wks, sibutramine, 10 mg, capsules, once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>ABT-991</other_name>
    <other_name>Meridia</other_name>
    <other_name>Reductil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sibutramine</intervention_name>
    <description>8-wks, sibutramine, 15 mg, capsules, once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>ABT-991</other_name>
    <other_name>Meridia</other_name>
    <other_name>Reductil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verapamil/trandolapril</intervention_name>
    <description>2 wk Run-in phase, antihypertensive therapy only</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol/HCT</intervention_name>
    <description>2 wk Run-in phase, antihypertensive therapy only</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>felodipine/ramipril</intervention_name>
    <description>2 wk Run-in phase, antihypertensive therapy only</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treated essential hypertension.

          -  Obesity: BMI 27-35 kg/m2

        Exclusion Criteria:

          -  Secondary hypertension.

          -  Stage 3 hypertension.

          -  Secondary obesity; BMI &gt; 35kg/m2.

          -  CAD; MI within past 6 months; NYHA stage 3 or 4 heart failure; tachyarrhythmia/atrial
             fibrillation; myocarditis.

          -  Kidney failure.

          -  Liver failure.

          -  Hyperthyroidism.

          -  Unstable DM.

          -  Carcinoma.

          -  Severe chronic infectious disease.

          -  Alcohol or drug abuse.

          -  Pregnancy.

          -  Epilepsy.

          -  Psychosis or treatment with antidepressants or major tranquilizers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>May 16, 2008</last_update_submitted>
  <last_update_submitted_qc>May 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Med J. Scholze</name_title>
    <organization>Director of Charite Medical OPD</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Felodipine</mesh_term>
    <mesh_term>Trandolapril</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

